Journal article
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
Abstract
BACKGROUND: For patients with UC, flexible maintenance dosing therapy may confer advantages for safety, efficacy, costs and patient preference. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC.
AIM: To assess the efficacy and safety of tofacitinib dose de-escalation and escalation in patients with UC.
Authors
Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel J; Lawendy N
Journal
Alimentary Pharmacology & Therapeutics, Vol. 51, No. 2, pp. 271–280
Publisher
Wiley
Publication Date
January 2020
DOI
10.1111/apt.15555
ISSN
0269-2813